Teglicar

• CAT Number: I018277
• CAS Number: 250694-07-6
• Molecular Formula: C₂₂H₄₅N₃O₃
• Molecular Weight: 399.61
• Purity: ≥95%
• Target: Endogenous Metabolite
• Storage: -20°C
• IUPAC Name: (3R)-3-(tetradecylcarbamoylamino)-4-(trimethylazaniumyl)butanoate
• InChI: InChI=1S/C22H45N3O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28)/t20-/m1/s1
• InChIKey: BMZYTDRMCBZVNH-HXUWFJFHSA-N
• SMILES: CCCCCCCCCCCCCCNC(=O)NC(CC(=O)[O-])C[N+](C)(C)C

Teglicar（Cat No.:I018277） is a specific and reversible inhibitor of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). By inhibiting L-CPT1, Teglicar reduces the process of ketogenesis and glucose production, leading to a decrease in gluconeogenesis. This mechanism helps improve glucose homeostasis and has potential antihyperglycemic properties. Teglicar holds promise as a therapeutic agent for the management of conditions characterized by dysregulated glucose metabolism, such as type 2 diabetes.

Reference

[1]. Conti R, et al. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes. 2011 Feb;60(2):644-51.